The Effect of Antihypertensive Medication Use on Fall Risk: A Randomized Controlled Trial

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The goal of this clinical trial is to compare the short-term effects of three commonly prescribed antihypertensive drug classes (beta-blockers, ACE inhibitors, and calcium channel blockers) on postural balance and fall risk in adults with newly diagnosed primary hypertension. The main questions it aims to answer are: * Do different antihypertensive drugs affect objective balance performance and fall risk? * What are the effects of these medications on dizziness and fear of falling? Researchers will use a balance analysis system (Biodex Balance System) and self-reported scales (Dizziness Handicap Inventory and Falls Efficacy Scale) to assess outcomes. Participants will: * Be randomly assigned to one of three drug groups (metoprolol, ramipril, or amlodipine) * Be evaluated at baseline (prior to treatment), at 2 weeks, and at 4 weeks after starting treatment * Complete balance tests and questionnaires at each time point This study aims to provide clinical insight into how commonly used blood pressure medications may impact balance and fall risk in real-world settings.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: f
View:

• Aged between 18 and 75 years

• Newly diagnosed with primary hypertension

• No prior use of antihypertensive medication

• No history of neurological, vestibular, orthopedic, or psychiatric conditions affecting balance

• Able to walk independently without assistive devices

• Provided written informed consent to participate in the study

Locations
Other Locations
Turkey
Bolu Abant Izzet Baysal University, Izzet Baysal Training and Research Hospital
RECRUITING
Bolu
Contact Information
Primary
Alp Ozel, PT, PhD
alpozel@ibu.edu.tr
+903742534520
Backup
Umut A Ugras, MD
umutataugras@gmail.com
+905066434435
Time Frame
Start Date: 2025-08-01
Estimated Completion Date: 2025-12-31
Participants
Target number of participants: 186
Treatments
Experimental: Beta Blocker Group
Participants will receive a beta blocker (e.g., Metoprolol) for antihypertensive treatment.
Experimental: ACE Inhibitor Group
Participants will receive an ACE inhibitor (e.g., Ramipril) for antihypertensive treatment.
Experimental: Calcium Channel Blocker Group
Participants will receive a calcium channel blocker (e.g., Amlodipine) for antihypertensive treatment.
Related Therapeutic Areas
Sponsors
Leads: Abant Izzet Baysal University

This content was sourced from clinicaltrials.gov